
|Videos|January 16, 2014
Treating NSCLC With Nintedanib
Author(s)Chandra P. Belani, MD
Chandra P. Belani, MD, discusses the VEGF-targeted agent nintedanib (BIBF 1120).
Advertisement
Chandra P. Belani, MD, Deputy Director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses the VEGF-targeted agent nintedanib (BIBF 1120).
Clinical Pearls:
- Nintedanib was studied in combination with docetaxel in a phase III randomized study of NSCLC
- This study showed an improvement in progression-free survival
- In a second trial, in combination with pemetrexed, nintedanib showed no benefit to progression-free survival
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5







































